Discontinued — last reported Q3 '25
Danaher Impairment Charges decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $15.00M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
An increase signals potential operational issues, poor past investment decisions, or adverse market conditions for specific business units.
These are non-cash charges recorded when the carrying value of an asset exceeds its fair market value. They indicate tha...
Often seen during restructuring or economic downturns across industrial sectors.
impairment_charges_cf| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $35.00M | $0.00 | $0.00 | $222.00M | $43.00M | $15.00M | $432.00M | $101.00M | $14.00M | $0.00 |
| QoQ Change | — | — | — | — | — | -100.0% | — | — | -80.6% | -65.1% | >999% | -76.6% | -86.1% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | +22.9% | — | — | -54.5% | -67.4% | -100.0% |
| Segment | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Life Sciences | $0.00 | $0.00 | $0.00 | $0.00 | $432.00M | — | — | $14.00M |
| Biotechnology | $13.50M | $13.50M | $13.50M | $0.00 | $15.00M | $0.00 | $86.00M | — |
| Biotechnology and Diagnostics | $19.25M | $19.25M | $19.25M | — | — | — | — | — |
| Diagnostics | $5.75M | $5.75M | $5.75M | $0.00 | — | — | — | — |
| Total | — | — | $35.00M | $222.00M | $15.00M | $432.00M | $101.00M | $14.00M |
Life Sciences, Biotechnology and Diagnostics Segment is derived from annual filings.
Biotechnology, Biotechnology and Diagnostics, Diagnostics, Life Sciences were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.